Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
Minghui Yin, Hongyi Tan, Shan Xie, Yun Kuang, Qian Wu, Junlong Ma, Chengxian Guo · 2026
Read Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database by Minghui Yin, Hongyi Tan, Shan Xie, Yun Kuang, Qian Wu, Junlong Ma, Chengxian Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13260334.txt.
Description
Minghui Yin and co-authors mined in 2026 a United States safety database for mental and nervous system side effects linked to three diabetes drugs. The drugs, canagliflozin, dapagliflozin, and empagliflozin, lower blood sugar by making the kidneys release glucose. Their search covered reports filed from late 2015 to late 2025.
From about 141,000 eligible reports, roughly one in thirteen involved neuropsychiatric events. Men and people aged 45 to 65 stood out as higher-risk groups in the data. Diabetic neuropathy appeared as a signal shared by all three drugs, while each drug also carried its own distinct signals. The authors stress that such database signals flag patterns to watch, not proof that a drug caused the events. They advise closer monitoring, especially for older patients and people using the drugs off-label.
Catalog record
| CREATOR | Minghui Yin, Hongyi Tan, Shan Xie, Yun Kuang, Qian Wu, Junlong Ma, Chengxian Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |